ID
37354
Beschrijving
Study ID: 111592 Clinical Study ID: 111592 Study Title: A Randomized, Double-blind, Placebo-controlled, Doseescalation Study to Assess the Anti-inflammatory Activity, Efficacy, and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury or ARDS Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996840 See https://clinicaltrials.gov/ct2/show/NCT00996840 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Placebo, SB-681323 Trade Name: N/A Study Indication: Lung Injury, Acute The primary objective of this phase 2 trial is to evaluate the safety and tolerability of intravenous dilmapimod/SB-681323 given in escalating dosages and over different intervals for three days in trauma patients at risk for the development of ALI or ARDS. This study consists of Screening, infusion of dilmapimod/SB-681323 on days 1-3, examination/sampling up to early day 5 (denoted as "Day 3 - 48 hrs") and a Follow-up on day 7. There are four cohorts, cohorts 1 and 3 receive the medication (or placebo) infusion over 4 hours, cohorts 2 and 4 over 24 hours. This form contains details on the administration of the investigational product and is to be filled in at Day 1, 2 and 3. Additionally, this form also contains Randomisation information and the assignment of the participant to one of the four cohorts for/prior to the first medication administration.
Link
https://clinicaltrials.gov/ct2/show/NCT00996840
Trefwoorden
Versies (2)
- 16-07-19 16-07-19 -
- 20-07-19 20-07-19 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
20 juli 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
SB-681323 in ALI/ARDS risk patients - NCT00996840
Investigational Product - IV Dosing, Randomisation, Cohort Assignment
Beschrijving
First Administration
Alias
- UMLS CUI-1
- C3469597
Beschrijving
Cohorts 1/3: 0-4 hrs Cohorts 2/4: 0-24hrs
Datatype
integer
Alias
- UMLS CUI [1,1]
- C0449238
- UMLS CUI [1,2]
- C3469597
- UMLS CUI [1,3]
- C0304229
Beschrijving
Start Date and Time
Datatype
datetime
Alias
- UMLS CUI [1]
- C3897500
Beschrijving
Stop Date and Time
Datatype
datetime
Alias
- UMLS CUI [1]
- C3899266
Beschrijving
Volume administered
Datatype
float
Maateenheden
- mL
Alias
- UMLS CUI [1]
- C2349139
Beschrijving
Administration post interruption
Alias
- UMLS CUI-1
- C3469597
- UMLS CUI-2
- C0687676
- UMLS CUI-3
- C1512900
Beschrijving
Cohorts 1/3: 0-4 hrs Cohorts 2/4: 0-24 hrs
Datatype
integer
Alias
- UMLS CUI [1,1]
- C0449238
- UMLS CUI [1,2]
- C3469597
- UMLS CUI [1,3]
- C0304229
Beschrijving
Start Date and Time
Datatype
datetime
Alias
- UMLS CUI [1]
- C3897500
Beschrijving
Stop Date and Time
Datatype
datetime
Alias
- UMLS CUI [1]
- C3899266
Beschrijving
Volume administered
Datatype
float
Maateenheden
- mL
Alias
- UMLS CUI [1]
- C2349139
Beschrijving
Investigational Product Container Number
Alias
- UMLS CUI-1
- C0304229
- UMLS CUI-2
- C0180098
- UMLS CUI-3
- C0600091
Beschrijving
Treatment Confirmation
Alias
- UMLS CUI-1
- C0750484
- UMLS CUI-2
- C0087111
Beschrijving
If no, record reasons
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0087111
- UMLS CUI [1,2]
- C2349182
Beschrijving
if applicable
Datatype
text
Alias
- UMLS CUI [1,1]
- C0566251
- UMLS CUI [1,2]
- C0087111
- UMLS CUI [1,3]
- C3827420
Beschrijving
Randomisation Number
Alias
- UMLS CUI-1
- C0034656
- UMLS CUI-2
- C0237753
Beschrijving
If yes, provide Randomisation Number and Date/time of randomisation
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0034656
- UMLS CUI [1,2]
- C0332149
Beschrijving
if applicable
Datatype
integer
Alias
- UMLS CUI [1,1]
- C0034656
- UMLS CUI [1,2]
- C0237753
Beschrijving
if applicable
Datatype
datetime
Alias
- UMLS CUI [1,1]
- C0034656
- UMLS CUI [1,2]
- C1264639
Similar models
Investigational Product - IV Dosing, Randomisation, Cohort Assignment
C1516050 (UMLS CUI [1,2])
C1264639 (UMLS CUI [1,3])
C3469597 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
C0687676 (UMLS CUI-2)
C1512900 (UMLS CUI-3)
C3469597 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
C0180098 (UMLS CUI-2)
C0600091 (UMLS CUI-3)
C0180098 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,3])
C0087111 (UMLS CUI-2)
C2349182 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])
C3827420 (UMLS CUI [1,3])
C0332149 (UMLS CUI [1,2])
C0237753 (UMLS CUI [1,2])
C1264639 (UMLS CUI [1,2])
Geen commentaren